DK2684571T3 - Immunomodulatoriske egenskaber for multipotente voksne progenitor celler og anvendelse deraf - Google Patents

Immunomodulatoriske egenskaber for multipotente voksne progenitor celler og anvendelse deraf Download PDF

Info

Publication number
DK2684571T3
DK2684571T3 DK13180503.8T DK13180503T DK2684571T3 DK 2684571 T3 DK2684571 T3 DK 2684571T3 DK 13180503 T DK13180503 T DK 13180503T DK 2684571 T3 DK2684571 T3 DK 2684571T3
Authority
DK
Denmark
Prior art keywords
multipotentent
progenitor cells
immunomodulatory properties
adult progenitor
adult
Prior art date
Application number
DK13180503.8T
Other languages
Danish (da)
English (en)
Inventor
Robert J Deans
Hof Wouter Van't
Richard Maziarz
Magdalena Kovacsovics
Philip Streeter
Original Assignee
Abt Holding Co
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abt Holding Co, Univ Oregon Health & Science filed Critical Abt Holding Co
Application granted granted Critical
Publication of DK2684571T3 publication Critical patent/DK2684571T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
DK13180503.8T 2005-11-09 2006-11-09 Immunomodulatoriske egenskaber for multipotente voksne progenitor celler og anvendelse deraf DK2684571T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/269,736 US8147824B2 (en) 1999-08-05 2005-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
EP06837336.4A EP1951294B1 (en) 2005-11-09 2006-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof

Publications (1)

Publication Number Publication Date
DK2684571T3 true DK2684571T3 (da) 2021-08-30

Family

ID=37808258

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13180503.8T DK2684571T3 (da) 2005-11-09 2006-11-09 Immunomodulatoriske egenskaber for multipotente voksne progenitor celler og anvendelse deraf
DK06837336.4T DK1951294T3 (da) 2005-11-09 2006-11-09 Immunomodulatoriske egenskaber af multipotent modne progenitorceller og anvendelse deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06837336.4T DK1951294T3 (da) 2005-11-09 2006-11-09 Immunomodulatoriske egenskaber af multipotent modne progenitorceller og anvendelse deraf

Country Status (19)

Country Link
US (6) US8147824B2 (enExample)
EP (3) EP1951294B1 (enExample)
JP (3) JP5399709B2 (enExample)
KR (1) KR101423786B1 (enExample)
CN (3) CN104873540B (enExample)
AU (1) AU2006311418B2 (enExample)
BR (1) BRPI0618486B1 (enExample)
CA (3) CA3206592A1 (enExample)
DK (2) DK2684571T3 (enExample)
ES (2) ES2884703T3 (enExample)
HU (1) HUE055956T2 (enExample)
IL (5) IL191317A (enExample)
LT (1) LT1951294T (enExample)
NZ (2) NZ596022A (enExample)
PH (2) PH12021551194A1 (enExample)
PL (2) PL2684571T3 (enExample)
PT (2) PT1951294T (enExample)
RU (1) RU2497530C2 (enExample)
WO (1) WO2007056578A1 (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP2305795B1 (en) 2000-12-06 2019-07-03 Celularity, Inc. Method of collecting placental stem cells
JP2004529621A (ja) * 2001-02-14 2004-09-30 ティー ファークト，レオ 多能性成体幹細胞、その起源、それを得る方法および維持する方法、それを分化させる方法、その使用法、ならびにそれ由来の細胞
WO2002064755A2 (en) * 2001-02-14 2002-08-22 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
AU2002243980B2 (en) 2001-02-14 2007-08-23 Robert J. Hariri Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
DE10144326B4 (de) * 2001-09-10 2005-09-22 Siemens Ag Verfahren und System zur Überwachung eines Reifenluftdrucks
US8192348B2 (en) * 2003-07-01 2012-06-05 Regents Of The University Of Minnesota Engineered blood vessels
EP1957633B1 (en) 2005-10-13 2013-12-18 Anthrogenesis Corporation Immunomodulation using placental stem cells
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
WO2007079184A2 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
EP2471903B1 (en) 2005-12-29 2018-02-14 Anthrogenesis Corporation Placental stem cell populations
CA2893204C (en) 2006-01-13 2016-11-29 Alla Danilkovitch Mesenchymal stem cells expressing tnf-.alpha. receptors
NZ744465A (en) 2006-01-23 2023-04-28 Abt Holding Co Mapc therapeutics without adjunctive immunosuppressive treatment
US20110171182A1 (en) * 2006-03-23 2011-07-14 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
KR20090076989A (ko) 2006-10-23 2009-07-13 안트로제네시스 코포레이션 태반 줄기세포군으로 뼈의 결함을 치료하기 위한 방법과 조성물
US9005964B2 (en) * 2006-11-24 2015-04-14 Regents Of The University Of Minnesota Endodermal progenitor cells
PL2120977T3 (pl) 2007-02-12 2013-12-31 Anthrogenesis Corp Leczenie chorób zapalnych z zastosowaniem łożyskowych komórek macierzystych
US8263065B2 (en) 2007-09-28 2012-09-11 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US20090162329A1 (en) * 2007-11-30 2009-06-25 Piero Anversa Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure
AU2008334058B2 (en) 2007-11-30 2014-07-10 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
EP2225362A1 (en) 2007-11-30 2010-09-08 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
EP2229177A1 (en) * 2007-11-30 2010-09-22 New York Medical College Methods of isolating non-senescent cardiac stem cells and uses thereof
CA2712496C (en) 2008-01-18 2021-01-12 Wei-Shou Hu Stem cell aggregates and methods for making and using
DK2329012T3 (da) 2008-08-20 2020-08-24 Celularity Inc Behandling af slagtilfælde under anvendelse af isolerede placentaceller
EP3172963B1 (en) 2008-08-20 2019-02-06 Celularity, Inc. Improved cell composition and methods of making the same
DK2331109T3 (da) 2008-08-22 2013-09-08 Anthrogenesis Corp Fremgangsmåder og sammensætninger til behandling af knogledefekter med placentale cellepopulationer
RU2562154C2 (ru) 2008-11-19 2015-09-10 Антродженезис Корпорейшн Амниотические адгезивные клетки
ES2690199T3 (es) * 2009-07-21 2018-11-19 Abt Holding Company Uso de células madre para reducir la extravasación de leucocitos
EP3831930A1 (en) * 2009-07-21 2021-06-09 ABT Holding Company Use of stem cells to reduce leukocyte extravasation
KR20120115602A (ko) 2010-01-26 2012-10-18 안트로제네시스 코포레이션 태반 줄기 세포를 사용한 골 관련 암의 치료
PT2556145T (pt) 2010-04-07 2016-10-25 Anthrogenesis Corp Angiogénese usando células estaminais placentárias
EP2555783A1 (en) 2010-04-08 2013-02-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
EP2568991B3 (en) * 2010-05-12 2018-11-28 ABT Holding Company Modulation of splenocytes in cell therapy
KR20230096132A (ko) 2010-07-13 2023-06-29 셀룰래리티 인코포레이티드 천연 킬러 세포의 생성 방법
US8642027B2 (en) 2010-09-01 2014-02-04 Stemnion, Inc. Compositions and methods for modulating ischemic injury
EP4663241A2 (en) 2010-10-08 2025-12-17 Mesoblast International Sàrl Enhanced msc preparations
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
US9040035B2 (en) 2011-06-01 2015-05-26 Anthrogenesis Corporation Treatment of pain using placental stem cells
SG10201914092XA (en) * 2011-06-06 2020-03-30 ReGenesys BVBA Expansion of stem cells in hollow fiber bioreactors
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
US9708584B2 (en) * 2011-12-01 2017-07-18 R Bio Co., Ltd. Medium composition for rejuvenating stem cells
US9828583B2 (en) 2012-01-13 2017-11-28 The General Hospital Corporation Isolated human lung progenitor cells and uses thereof
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
JP2016506968A (ja) 2013-02-05 2016-03-07 アントフロゲネシス コーポレーション 胎盤由来のナチュラルキラー細胞
US20160002597A1 (en) 2013-02-12 2016-01-07 Reneuron Limited Method of producing microparticles
EP3795159A1 (en) * 2013-04-12 2021-03-24 Houston Methodist Hospital Improving organs for transplantation
ES2753323T3 (es) * 2013-04-30 2020-04-08 Univ Leuven Kath Terapia celular para síndromes mielodisplásicos
EP3068867B1 (en) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expanding cells in a bioreactor
ITFI20130303A1 (it) * 2013-12-24 2015-06-25 Azienda Ospedaliero Universitaria M Eyer Metodica per l¿isolamento, purificazione ed amplificazione di progenitori renali cd133+cd24+ dalle urine di pazienti affetti da malattie renali.
CN106232800B (zh) 2014-03-25 2020-07-03 泰尔茂比司特公司 介质的被动替代
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
RU2580640C1 (ru) * 2014-12-25 2016-04-10 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Способ профилактики гуморального отторжения при аво-несовместимой трансплантации печени детям раннего возраста
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
SG11201806245TA (en) 2016-01-21 2018-08-30 Abt Holding Co Stem cells for wound healing
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
WO2018184028A2 (en) 2017-03-31 2018-10-04 Terumo Bct, Inc. Cell expansion
JP7102397B2 (ja) 2017-04-03 2022-07-19 株式会社カネカ 間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN107714726A (zh) * 2017-10-16 2018-02-23 中国科学院广州生物医药与健康研究院 一种重塑骨髓微环境的方法
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
EP3733838A4 (en) 2017-12-28 2021-11-03 Kaneka Corporation CELL POPULATION WITH ADHESIVE STEM CELLS, METHOD FOR MANUFACTURING SUCH CELL POPULATION AND PHARMACEUTICAL COMPOSITION
JP7454379B2 (ja) 2017-12-28 2024-03-22 株式会社カネカ 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN109735611A (zh) * 2018-12-19 2019-05-10 珠海铂华生物工程有限公司 一种用于检测骨髓衰竭综合征的基因组合、引物库、构建高通量测序文库的方法及其应用
JPWO2020184350A1 (enExample) 2019-03-08 2020-09-17
JP7705950B2 (ja) 2021-03-23 2025-07-10 テルモ ビーシーティー、インコーポレーテッド 細胞を増殖する方法
US20250002856A1 (en) 2021-11-05 2025-01-02 Healios KK. Culture-expanded canine progenitor cells and related methods
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
EP4580643A1 (en) * 2022-09-02 2025-07-09 Medical and Pharmaceutical Industry Technology and Development Center Use of composition including mesenchymal stem cells for alleviating myelofibrosis

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
JPH0628570B2 (ja) 1986-02-13 1994-04-20 雪印乳業株式会社 カプセル体の製造方法及び装置
EP0301777A1 (en) 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
US5089272A (en) 1989-03-29 1992-02-18 Snow Brand Milk Products Co., Ltd. Process for producing capsules having a permeability-controllable membrane
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
DE69430824T2 (de) 1993-08-12 2003-01-23 Neurotech S.A., Evry Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
JPH07316051A (ja) 1994-05-23 1995-12-05 Kanegafuchi Chem Ind Co Ltd 免疫抑制剤としてのベルベリン
IN184685B (enExample) * 1996-02-14 2000-09-23 Nat Inst Immunology
US6306434B1 (en) 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
US20030103951A1 (en) 1997-07-14 2003-06-05 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
DE69831957T3 (de) * 1997-07-14 2009-07-23 Osiris Therapeutics, Inc. Herzmuskelregenerierung unter verwendung mesenchymaler stammzellen
US7514074B2 (en) * 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
JP4441115B2 (ja) * 1998-03-13 2010-03-31 オシリス セラピューティクス，インコーポレイテッド ヒト非自己間葉幹細胞を使用する方法と利用
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US6328960B1 (en) * 1998-03-18 2001-12-11 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
DE69910362T2 (de) * 1998-04-03 2004-06-24 Osiris Therapeutics, Inc. Anwendung der mesenchymalen stammzellen als immunsuppressiva
ATE458822T1 (de) * 1998-04-08 2010-03-15 Metabolix Inc Verfahren für die trennung und reinigung von biopolymeren
CA2244554A1 (en) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
US6060364A (en) * 1999-03-02 2000-05-09 Advanced Micro Devices, Inc. Fast Mosfet with low-doped source/drain
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
JP5398941B2 (ja) * 1999-08-05 2014-01-29 エイビーティー ホールディング カンパニー 多能性成体幹細胞およびそれを単離する方法
US6685936B2 (en) * 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US7163808B2 (en) 2000-11-20 2007-01-16 California Institute Of Technology Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor
US20030044843A1 (en) 2001-01-09 2003-03-06 Mitsubishi Pharma Corporation Novel proteome analysis method and devices therefor
JP2004529621A (ja) * 2001-02-14 2004-09-30 ティー ファークト，レオ 多能性成体幹細胞、その起源、それを得る方法および維持する方法、それを分化させる方法、その使用法、ならびにそれ由来の細胞
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
WO2003060085A2 (en) 2002-01-14 2003-07-24 The Board Of Trustees Of The University Of Illinois Mammalian neural stem cells, compositions and uses thereof
US20040037811A1 (en) 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
US7105037B2 (en) * 2002-10-31 2006-09-12 Advanced Technology Materials, Inc. Semiconductor manufacturing facility utilizing exhaust recirculation
US7807458B2 (en) 2003-01-30 2010-10-05 The United States Of America As Represented By The Secretary Of The Department Of Veterans Affairs Multilineage-inducible cells and uses thereof
WO2004099395A2 (en) 2003-05-08 2004-11-18 Cellartis Ab A method for the generation of neural progenitor cells
AU2004252568B2 (en) * 2003-06-27 2011-06-30 Ethicon, Incorporated Regeneration and repair of neural tissue using postpartum-derived cells
WO2005003320A2 (en) * 2003-07-02 2005-01-13 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
EP1737947B9 (en) 2004-04-21 2012-04-25 Regents Of The University Of Minnesota Mapc generation of lung tissue
CA2607213A1 (en) 2005-05-05 2006-11-16 Regents Of The University Of Minnesota Use of nk cell inhibition to facilitate persistence of engrafted mhc- i negative cells
AU2005331534B2 (en) 2005-05-05 2011-12-08 Regents Of The University Of Minnesota Use of MAPC or progeny therefrom to populate lymphohematopoietic tissues
TW200726474A (en) 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
CA2624916A1 (en) 2005-10-13 2007-04-26 Anthrogenesis Corporation Production of oligodendrocytes from placenta-derived stem cells
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
NZ744465A (en) 2006-01-23 2023-04-28 Abt Holding Co Mapc therapeutics without adjunctive immunosuppressive treatment
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
PL2120977T3 (pl) 2007-02-12 2013-12-31 Anthrogenesis Corp Leczenie chorób zapalnych z zastosowaniem łożyskowych komórek macierzystych
US20120121545A1 (en) 2009-01-15 2012-05-17 Corestem Co., Ltd. Pharmaceutical Composition For Bone Disease Treatment Or Countering Inflammation, Comprising Cartilage Stem Cells As An Active Principle
EP2241617A1 (en) 2009-04-06 2010-10-20 Rijksuniversiteit Groningen Multipotent cells derived from blood and methods and uses related thereto

Also Published As

Publication number Publication date
JP2009514979A (ja) 2009-04-09
US20060263337A1 (en) 2006-11-23
EP2684571A1 (en) 2014-01-15
IL191317A (en) 2015-03-31
JP2013256510A (ja) 2013-12-26
EP1951294A1 (en) 2008-08-06
CA2628254C (en) 2023-06-20
BRPI0618486B1 (pt) 2021-11-30
CN104873540B (zh) 2019-11-15
AU2006311418B2 (en) 2013-03-14
PL1951294T3 (pl) 2020-08-24
IL276705A (en) 2020-09-30
IL249572B (en) 2020-08-31
LT1951294T (lt) 2020-04-10
US20210346429A1 (en) 2021-11-11
CA3028315A1 (en) 2007-05-18
DK1951294T3 (da) 2020-03-23
JP6342880B2 (ja) 2018-06-13
US9808485B2 (en) 2017-11-07
IL191317A0 (en) 2008-12-29
US9962407B2 (en) 2018-05-08
PT1951294T (pt) 2020-03-31
HK1203058A1 (en) 2015-10-16
PH12015502169A1 (en) 2017-04-24
PL2684571T3 (pl) 2022-01-10
RU2008122943A (ru) 2009-12-20
RU2497530C2 (ru) 2013-11-10
JP2016135763A (ja) 2016-07-28
IL276705B (en) 2022-04-01
CN104873540A (zh) 2015-09-02
EP2684571B1 (en) 2021-05-26
EP3808373A1 (en) 2021-04-21
EP1951294B1 (en) 2019-12-25
IL289024A (en) 2022-02-01
KR20080092336A (ko) 2008-10-15
HK1214166A1 (zh) 2016-07-22
AU2006311418A1 (en) 2007-05-18
WO2007056578A1 (en) 2007-05-18
IL236832A (en) 2017-08-31
BRPI0618486A2 (pt) 2011-08-30
US11197889B2 (en) 2021-12-14
CN101336112B (zh) 2015-05-20
US8147824B2 (en) 2012-04-03
US20120135043A1 (en) 2012-05-31
KR101423786B1 (ko) 2014-07-25
NZ596022A (en) 2013-06-28
JP5897514B2 (ja) 2016-03-30
CA3206592A1 (en) 2007-05-18
PT2684571T (pt) 2021-08-30
JP5399709B2 (ja) 2014-01-29
IL249572A0 (en) 2017-02-28
CN104095878B (zh) 2020-01-21
HUE055956T2 (hu) 2022-01-28
ES2778424T3 (es) 2020-08-10
ES2884703T3 (es) 2021-12-10
CN104095878A (zh) 2014-10-15
US20180055881A1 (en) 2018-03-01
PH12015502169B1 (en) 2022-02-11
US20090104163A1 (en) 2009-04-23
CA3028315C (en) 2023-09-05
US20150118193A1 (en) 2015-04-30
NZ568546A (en) 2012-06-29
CA2628254A1 (en) 2007-05-18
CN101336112A (zh) 2008-12-31
PH12021551194A1 (en) 2023-04-24

Similar Documents

Publication Publication Date Title
DK2684571T3 (da) Immunomodulatoriske egenskaber for multipotente voksne progenitor celler og anvendelse deraf
DK1924577T3 (da) Substituerede benzimidazoler og fremgangsmåder til fremstilling
IS8210A (is) Skilgreining krafna um lögun og athugun hvort lögun hlutar samræmist theim
DK1969391T3 (da) Tyndfilm emitter-absorber indretning og fremgangsmåde
EP2234486A4 (en) BENZIMIDAZOLES AND ANALOGS AS INHIBITORS OF RHO-KINASE
IL200639A0 (en) Benzimidazole derivatives and methods of use thereof
KR101413615B9 (ko) 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
PL2214656T3 (pl) Kompozycje i sposoby wzmacniania odpowiedzi immunologicznej
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2160336T3 (da) Forbindelsesmekanisme og fremgangsmåde
JP2006122056A5 (ja) β-グルカンの使用
BRPI0821244A2 (pt) Proteína de cereal hipoalergênica e seus usos
DK1922309T3 (da) N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
DK1885716T3 (da) Thiazolderivater og anvendelse deraf
DK1863801T3 (da) Benzimidazolderivat og anvendelse deraf
ATE517098T1 (de) Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren
DK1858481T3 (da) Ophthalmologiske sammensætninger og anvendelse deraf
EP1907533A4 (en) PROGENITOR CELLS AND USES THEREOF
EP1845984A4 (en) METHYLPHENIDATE DERIVATIVES AND THEIR USES
NO20054698D0 (no) Elastomerblanding og fremgangsmate for fremstilling derav
FR2892015B1 (fr) Prothese erectile gonflable
ZA200800536B (en) Substituted benzimidazoles and methods of preparation
ES1062720Y (es) Cuna balancin